K.G. van der Hem

483 total citations
16 papers, 268 citations indexed

About

K.G. van der Hem is a scholar working on Hematology, Molecular Biology and Genetics. According to data from OpenAlex, K.G. van der Hem has authored 16 papers receiving a total of 268 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Hematology, 5 papers in Molecular Biology and 4 papers in Genetics. Recurrent topics in K.G. van der Hem's work include Acute Myeloid Leukemia Research (4 papers), Chronic Lymphocytic Leukemia Research (4 papers) and Multiple Myeloma Research and Treatments (4 papers). K.G. van der Hem is often cited by papers focused on Acute Myeloid Leukemia Research (4 papers), Chronic Lymphocytic Leukemia Research (4 papers) and Multiple Myeloma Research and Treatments (4 papers). K.G. van der Hem collaborates with scholars based in Netherlands and United States. K.G. van der Hem's co-authors include Marinus H. J. van Oers, G.J. Ossenkoppele, Michel van Agthoven, Pieter Sonneveld, G. Verhoef, Jeanette K. Doorduijn, Bronno van der Holt, M Schaafsma, LF Verdonck and M Krámer and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Urology and British Journal of Cancer.

In The Last Decade

K.G. van der Hem

16 papers receiving 262 citations

Peers

Countries citing papers authored by K.G. van der Hem

Since Specialization

Citations

This map shows the geographic impact of K.G. van der Hem's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by K.G. van der Hem with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites K.G. van der Hem more than expected).

Fields of papers citing papers by K.G. van der Hem

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by K.G. van der Hem. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by K.G. van der Hem. The network helps show where K.G. van der Hem may publish in the future.

Co-authorship network of co-authors of K.G. van der Hem

This figure shows the co-authorship network connecting the top 25 collaborators of K.G. van der Hem. A scholar is included among the top collaborators of K.G. van der Hem based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with K.G. van der Hem. K.G. van der Hem is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

#	Work	Indexed citations
1	Treatment sequences and drug costs from diagnosis to death in multiple myeloma 2023 ·European Journal Of Haematology ·(unknown), (unknown), Kevin Groen, Marjolein L. Donker, K.G. van der Hem, M. Westerman, A.M. Gerrits, Aart Beeker, Niels W.C.J. van de Donk, Hedwig M. Blommestein, Sonja Zweegman	1
2	Quality of life of patients with chronic lymphocytic leukaemia in the Netherlands: results of a longitudinal multicentre study 2015 ·Quality of Life Research ·(unknown), Martyn Ronald Schaafsma, Peter Joosten, E.F.M. Posthuma, S. Wittebol, Peter C. Huijgens, (unknown), Gerard Vreugdenhil, Hein P. J. Visser, W Peters, Z. Erjavec, P. Wijermans, Simon Daenen, K.G. van der Hem, Marinus H. J. van Oers, Carin A. Uyl‐de Groot	36
3	Real-world costs of chronic lymphocytic leukaemia in the Netherlands 2013 ·Leukemia Research ·(unknown), (unknown), M. Ronald Schaafsma, Okke de Weerdt, Peter Joosten, E.F.M. Posthuma, S. Wittebol, Peter C. Huijgens, (unknown), Gerard Vreugdenhil, Hein P. J. Visser, W Peters, Z. Erjavec, P. W. Wijermans, Simon Daenen, K.G. van der Hem, Marinus H. J. van Oers, Carin A. Uyl‐de Groot	8
4	Human soluble TRAIL/Apo2L induces apoptosis in a subpopulation of chemotherapy refractory nodal diffuse large B‐cell lymphomas, determined by a highly sensitive in vitro apoptosis assay 2006 ·British Journal of Haematology ·Saskia A.G.M. Cillessen, Chris J.L.M. Meijer, Gert J. Ossenkoppele, Kitty C. M. Castricum, August H. Westra, (unknown), Jettie J.F. Muris, (unknown), K.G. van der Hem, Marcel J. Flens, Erik Hooijberg, Joost J. Oudejans	12
5	Cost analysis of common treatment options for indolent follicular non-Hodgkin's lymphoma. 2005 ·PubMed ·Michel van Agthoven, Mark H.H. Kramer, Pieter Sonneveld, K.G. van der Hem, Peter C. Huijgens, Pierre W. Wijermans, Hanneke C. Kluin‐Nelemans, M. Ronald Schaafsma, Douwe H. Biesma, Vera Mattijssen, Carin A. Uyl‐de Groot, Anton Hagenbeek	14
6	CHOP Compared With CHOP Plus Granulocyte Colony-Stimulating Factor in Elderly Patients With Aggressive Non-Hodgkin’s Lymphoma 2003 ·Journal of Clinical Oncology ·Jeanette K. Doorduijn, Bronno van der Holt, Gustaaf W. van Imhoff, K.G. van der Hem, M Krámer, Marinus H. J. van Oers, G.J. Ossenkoppele, M Schaafsma, LF Verdonck, G. Verhoef, Monique Steijaert, (unknown), C.A. Uyl-de Groot, Michel van Agthoven, A Mulder, Pieter Sonneveld	132
7	Late-onset cardiotoxicity of chemotherapy and radiotherapy. 2003 ·PubMed ·Birgit M. Dietz, K.G. van der Hem	1
8	Effects of bryostatin-1 on chronic myeloid leukaemia-derived haematopoietic progenitors 1999 ·British Journal of Cancer ·S. F. T. Thijsen, G.J. Schuurhuis, J W van Oostveen, (unknown), K.G. van der Hem, (unknown), A.M. Dräger, G. J. Ossenkoppele	5
9	Heterogenous effects of bryostatin on human myeloid leukemia clonogenicity: Dose and time scheduling dependency 1996 ·Leukemia Research ·K.G. van der Hem, Gerrit Jan Schuurhuis, Angelika M. Dräger, (unknown), Peter C. Huijgens	2
10	High-dose melphalan with re-infusion of unprocessed, G-CFS-primed whole blood is effective and non-toxic therapy in multiple myeloma 1996 ·European Journal of Cancer ·G.J. Ossenkoppele, G.J. Schuurhuis, Andries R. Jonkhoff, K.G. van der Hem, (unknown), (unknown), August H. Westra, A.M. Dräger, P.C. Huijgens	10
11	Effects of bryostatin-5 and hematopoietic growth factors on acute myeloid leukemia cell differentiation, proliferation, and primary plating efficiency 1995 ·Leukemia Research ·K.G. van der Hem, Angelika M. Dräger, (unknown), Peter C. Huijgens	4
12	Bryostatin-5 stimulates normal human hematopoiesis and inhibits proliferation of HL60 leukemic cells 1995 ·Leukemia Research ·K.G. van der Hem, Angelika M. Dräger, (unknown), M. M. A. C. Langenhuijsen, Peter C. Huijgens	7
13	The differentiation inducing effect of bryostatin 5 on human myeloid blast cells is potentiated by vitamin D3. 1994 ·PubMed ·K.G. van der Hem, A.M. Dräger, (unknown), (unknown), W. Devillé, M. M. A. C. Langenhuijsen	13
14	Malignant Leydig Cell Tumor of the Testis in Complete Remission on o, p′-Dichlorodiphenyl-Dichloroethane 1992 ·The Journal of Urology ·K.G. van der Hem, Epie Boven, (unknown), Herbert M. Pinedo	15
15	Late relapse of testicular cancer. A case report and a review of the literature. 1991 ·PubMed ·K.G. van der Hem, C.J. van Groeningen, Herbert M. Pinedo	1
16	Bilateral Excision of Perinephric Fat and Fascia (Gerota’s Fasciectomy) in the Treatment of Intractable Chyluria 1991 ·The Journal of Urology ·M. Oudkerk Pool, K.G. van der Hem, Herbert V. Stel, W. J. Luth, (unknown), Rijk O. B. Gans	7

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact